Ciprofloxacin for the Prevention of Meningococcal Meningitis

Status Completed

Clinical Trial Summary

This study evaluates the effect of antibiotic prophylaxis with ciprofloxacin, given to the contacts of meningitis cases, on the overall attack rate of meningitis during an epidemic. One third of enrolled villages will receive standard care; in one-third of villages, household contacts of meningitis cases will be offered a single dose of oral ciprofloxacin; and in one-third of villages, the entire village will be offered a single dose of oral ciprofloxacin after the notification of the first case in the village.

Clinical Trial Description

Antibiotic prophylaxis is not currently recommended for contacts of cases during a meningitis epidemic in the African Meningitis Belt. Reactive vaccination campaigns are the preferred strategy for prevention during an epidemic.

A novel strain of meningococcus, Neisseria meningitidis serogroup C (NmC), began circulating in Nigeria in 2013 and caused a major epidemic with over 10 000 cases in Nigeria and Niger in 2015.

There is currently a global shortage of vaccine against NmC, and a recent WHO expert panel called for the formal evaluation of antibiotic prophylaxis as another epidemic response strategy.

When taken as a single dose, oral ciprofloxacin effectively eliminates nasopharyngeal carriage of meningococcus.

This trial aims to investigate two different antibiotic prophylaxis strategies during an epidemic of meningococcal meningitis: ciprofloxacin prophylaxis to household members of cases and village-wide prophylaxis after the notification of a case in a village. These two strategies will be compared to villages receiving standard care. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02724046
Study type	Interventional
Source	Epicentre
Contact
Status	Completed
Phase	Phase 4
Start date	April 22, 2017
Completion date	June 12, 2017

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04689191` - A Phase III Clinical Trial of the Group A and C Meningococcal Polysaccharide Vaccine	Phase 3
Recruiting	`NCT04689165` - A Phase III Clinical Trial of the Group A Meningococcal Polysaccharide Vaccine	Phase 3
Completed	`NCT00780806` - Safety And Blood Collection Study Of Meningococcal B Rlp2086 Vaccine In Adults	Phase 1/Phase 2
Completed	`NCT03378258` - Petechiae In Children (PIC) Study: Defining A Clinical Decision Rule for The Management Of Fever and Non-Blanching Rashes In Children Including The Role Of Point Of Care Testing For Procalcitonin & Neisseria Meningitidis DNA.
Completed	`NCT03205371` - Immunogenicity and Safety of a Meningococcal Conjugate Vaccine Given Concomitantly With Other Vaccines in Toddlers	Phase 3
Completed	`NCT01352793` - A Global Phase 3 Safety Study of 120 mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years	Phase 3
Not yet recruiting	`NCT06113198` - A Study on the Immune Response and Safety of a Vaccine Against N. Meningitidis Serogroup B Infection in Healthy Infants From 2 Months of Age	Phase 4
Completed	`NCT03295318` - Clinical Study of Meningococcal ACYWX Conjugate Vaccine, in 12-16 Month Olds	Phase 2
Completed	`NCT03493919` - A Sourcing Study to Collect Human Blood Samples From Healthy Adults	Phase 4
Completed	`NCT00474526` - A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Infants	Phase 3
Completed	`NCT00297687` - Study Evaluating the Safety, Immunogenicity and Tolerability of Meningococcal Group B Vaccine in Healthy Adults	Phase 1
Recruiting	`NCT04665791` - A Human Controlled Infection Study With Neisseria Lactamica in Malian Adults	N/A
Withdrawn	`NCT03431675` - Ciprofloxacin for the Prevention of Meningococcal Meningitis 2018	Phase 4
Recruiting	`NCT02878291` - Safety Study of Meningococcal ACYW135 Polysaccharide Conjugate Vaccine in Healthy Volunteers Aged Above 3 Months	Phase 1
Completed	`NCT00314041` - Study Evaluating the Tolerance of Conjugate Meningococcal C Vaccine in Infants	Phase 2
Recruiting	`NCT04685850` - Long-term Sequelae of Childhood Meningitis and Meningococcal Purpura Fulminans
Completed	`NCT03587207` - Study to Assess Potential Immune Interference When GlaxoSmithKline (GSK) Biologicals' MenABCWY Vaccine is Administered to Healthy Subjects Aged 10-25 Years	Phase 2
Completed	`NCT03824093` - High and Low Resource Interventions to Promote HPV Vaccines	N/A
Completed	`NCT04707391` - Immunogenicity and Safety Study of GSK's MenABCWY Vaccine in Healthy Adolescents and Adults Previously Primed With MenACWY Vaccine	Phase 3
Terminated	`NCT00798304` - Study Evaluating Safety, Tolerability, and Immunogenicity of Meningococcal B Vaccine in Healthy Infants	Phase 2